Researchers take a fresh look at hallucinogens

For decades the study of the therapeutic potential of hallucinogens had been badly discredited by the outsized claims made by researchers back in the 1960s. But new research has highlighted the potential therapeutic value of hallucinogens like the mushroom psilocybin for treating depression in cancer victims, post-traumatic stress disorder, obsessive-compulsive disorder, addiction, end-of-life stress and more. Subjects have described intense spiritual experiences similar to religious mystics. Article

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.